Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial

British Journal of Cancer

Volumn 102, Issue 1, 2010, Pages 68-72

  Bengala, C ^a   Bertolini, F ^a   Malavasi, N ^a   Boni, C ^b   Aitini, E ^c   Dealis, C ^a   Zironi, S ^a   Depenni, R ^a   Fontana, A ^a   Del Giovane, C ^a   Luppi, G ^a   Conte, P ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c CARLO POMA HOSPITAL   (Italy)

Author keywords

Biliary tract cancer; Phase II trial; Sorafenib

Indexed keywords

SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; LUNG EMBOLISM; MALE; METABOLIC DISORDER; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BILE DUCT NEOPLASMS; BILIARY TRACT NEOPLASMS; CARCINOMA; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; FATIGUE; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; SALVAGE THERAPY;

EID: 74249098818     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605458     Document Type: Article

References (28)

1. Adjei AA, Christian M, Ivy P (2009) Novel designs and end points for phase II clinical trials. Clin Cancer Res 15: 1866-1872
2. Beeram M, Patnaik A, Rowinsky EK (2005) RAF a strategic target for therapeutic development against cancer. J Clin Oncol 23: 6771-6790
3. Berardi R, Scartozzi M, Freddari F, Squadroni M, Santinelli A, Bearzi I, Fabris G, Cascinu S (2006) Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review. Cancer Treat Rew 32: 333-347
4. Clark JW, Meyerhardt JA, Sahani DV, Namasivayam S, Abrams TA, Stuart K, Bhargava P, Blaszkowsky LS, Jain SR, Zhu AX (2007) Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gallbladder cancers. J Clin Oncol 25: 18S (Suppl; abstract 4625)
5. Dal Lago L, D'Hondt V, Awada A (2008) Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumor. Oncologist 13: 845-858
6. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341: 1368-1378
7. Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96: 896-902
8. El-Khoureiry AB, Rankin C, Lenz HJ, Philip P, Rivkin SE, Blanke CD (2007) SWOG 0514: a phase II study of sorafenib (BAY43-9006) as single agent in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J Clin Oncol 25: 18s: 4639
9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134
10. Fong Y, Blumgart LH, Lin E, Fortner JG, Brennan MF (1996) Outcome of treatment for distal bile duct cancer. Br J Cancer 83: 1712-1715
11. Fong Y, Kemeny N, Lawrence TS (2001) Cancer of the liver and biliary tree. In Cancer: Principles and Practice of Oncology, DeVita VT, Hellmam S, Rosenberg SA (eds), pp 1178-1203. Lippincott-Raven: Philadelphia (PA)
12. Furuse J, Okusaka H, Miyazaki M, Taniai H, Nimura N, BT22 Study Group (2009) A randomized study of gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary tract cancer. J Clin Oncol 27: 15s, (Suppl; abstract 4579)
13. Hezel AF, Zhu AX (2008) Systemic therapy for biliary tract cancers. The Oncologist 13: 415-423
14. Huether A, Hopfner M, Baradari V, Schuppan D, Scherübl H (2007) Sorafenib alone or in combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 73: 1308-1317
15. Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D, Javle MM (2007) A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 14: 3202-3209
16. Kawahara N, Ono M, Taguchi K, Okamoto M, Shimada M, Takenaka K, Hayashi K, Mosher DF, Sugimachi K, Tsuneyoshi M, Kuwano M (1998) Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 28(6): 1512-1517
17. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH (2009) Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27(10): 1675-1684
18. LaRocca RV, Hicks MD, Foreman B (2007) Effective palliation of advanced cholangiocarcinoma with sorafenib: a two patient case report. J Gastrointest Cancer 38: 154-156
19. Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, Nervi F (2001) Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51: 349-364
20. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group (2008a) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390
21. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, Panel of Experts in HCC-Design Clinical Trials (2008b) Design and endpoints of clinical trials in hepatocellular carcinoma. J Nat Cancer Inst 100: 698-711
22. Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS (2008) Phase II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 53: 564-570
23. Strumberg D, Richly H, Hilger RA, Scleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965-972 (Pubitemid 46202316)
24. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C (2003) Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52: 706-712 (Pubitemid 36528874)
25. Takimoto CH, Awada A (2008) Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 61: 535-548
26. Thongprasert S, Napapan S, Charoentum C, Moonprakan S (2005) Phase II study of gemcitabine and cisplatin as first line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16: 279-281
27. Valle JW, Wasan HS, Palmer DD, Cunningham D, Anthoney DA, Maraveyas A, Hughes SK, Roughton M, Bridgewater JA (2009) Results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol; 27: 15s (Suppl; abstract 4503)
28. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64: 7099-7109